Raiffeisen Bank International AG Sells 235 Shares of Axon Enterprise, Inc $AXON

Raiffeisen Bank International AG trimmed its position in Axon Enterprise, Inc (NASDAQ:AXON) by 11.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,817 shares of the biotechnology company’s stock after selling 235 shares during the quarter. Raiffeisen Bank International AG’s holdings in Axon Enterprise were worth $1,426,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. TCTC Holdings LLC increased its stake in shares of Axon Enterprise by 75.0% in the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 24 shares in the last quarter. Banque Transatlantique SA bought a new position in Axon Enterprise in the 1st quarter worth $31,000. Flaharty Asset Management LLC bought a new position in Axon Enterprise in the 1st quarter worth $33,000. Hemington Wealth Management increased its stake in Axon Enterprise by 70.8% in the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock worth $33,000 after buying an additional 17 shares in the last quarter. Finally, Whipplewood Advisors LLC raised its holdings in Axon Enterprise by 192.9% during the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 27 shares during the period. Institutional investors own 79.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on AXON. UBS Group dropped their price objective on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Bank of America boosted their price target on Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $870.00 price objective on shares of Axon Enterprise in a report on Wednesday, September 24th. The Goldman Sachs Group reduced their price objective on shares of Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Finally, Cowen reissued a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Fifteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $814.00.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $533.77 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. Axon Enterprise, Inc has a 1-year low of $469.24 and a 1-year high of $885.91. The business has a 50 day simple moving average of $694.97 and a two-hundred day simple moving average of $734.66. The stock has a market capitalization of $42.12 billion, a PE ratio of 131.80, a P/E/G ratio of 29.49 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm had revenue of $710.64 million for the quarter, compared to the consensus estimate of $704.83 million. During the same quarter in the prior year, the company posted $1.45 earnings per share. The firm’s revenue was up 30.6% compared to the same quarter last year. On average, research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In related news, CFO Brittany Bagley sold 5,000 shares of the stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $713.88, for a total value of $3,569,400.00. Following the completion of the transaction, the chief financial officer owned 93,592 shares of the company’s stock, valued at approximately $66,813,456.96. This trade represents a 5.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $743.64, for a total value of $7,436,400.00. Following the completion of the transaction, the chief executive officer owned 3,043,982 shares of the company’s stock, valued at approximately $2,263,626,774.48. This represents a 0.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 38,622 shares of company stock worth $26,439,364 over the last three months. 4.40% of the stock is owned by company insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.